1. Home
  2. GDHG vs AIM Comparison

GDHG vs AIM Comparison

Compare GDHG & AIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GDHG
  • AIM
  • Stock Information
  • Founded
  • GDHG 2008
  • AIM 1966
  • Country
  • GDHG China
  • AIM United States
  • Employees
  • GDHG N/A
  • AIM N/A
  • Industry
  • GDHG Services-Misc. Amusement & Recreation
  • AIM Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • GDHG Consumer Discretionary
  • AIM Health Care
  • Exchange
  • GDHG Nasdaq
  • AIM Nasdaq
  • Market Cap
  • GDHG 9.0M
  • AIM 8.8M
  • IPO Year
  • GDHG 2023
  • AIM N/A
  • Fundamental
  • Price
  • GDHG $0.50
  • AIM $0.12
  • Analyst Decision
  • GDHG
  • AIM Strong Buy
  • Analyst Count
  • GDHG 0
  • AIM 2
  • Target Price
  • GDHG N/A
  • AIM $2.75
  • AVG Volume (30 Days)
  • GDHG 4.5M
  • AIM 476.8K
  • Earning Date
  • GDHG 04-08-2025
  • AIM 03-27-2025
  • Dividend Yield
  • GDHG N/A
  • AIM N/A
  • EPS Growth
  • GDHG N/A
  • AIM N/A
  • EPS
  • GDHG N/A
  • AIM N/A
  • Revenue
  • GDHG $22,333,251.00
  • AIM $170,000.00
  • Revenue This Year
  • GDHG N/A
  • AIM N/A
  • Revenue Next Year
  • GDHG N/A
  • AIM $1,693.10
  • P/E Ratio
  • GDHG N/A
  • AIM N/A
  • Revenue Growth
  • GDHG N/A
  • AIM N/A
  • 52 Week Low
  • GDHG $0.39
  • AIM $0.11
  • 52 Week High
  • GDHG $22.75
  • AIM $0.62
  • Technical
  • Relative Strength Index (RSI)
  • GDHG 37.98
  • AIM 42.13
  • Support Level
  • GDHG $0.72
  • AIM $0.11
  • Resistance Level
  • GDHG $5.25
  • AIM $0.16
  • Average True Range (ATR)
  • GDHG 0.91
  • AIM 0.01
  • MACD
  • GDHG -0.07
  • AIM 0.00
  • Stochastic Oscillator
  • GDHG 2.34
  • AIM 5.00

About GDHG Golden Heaven Group Holdings Ltd.

Golden Heaven Group Holdings Ltd is an offshore holding company. Through the operating entities in China, It manages and operates six properties consisting of amusement parks, water parks, and complementary recreational facilities. The parks offer a broad selection of exhilarating and recreational experiences, including both thrilling and family-friendly rides, water attractions, gourmet festivals, circus performances, and high-tech facilities. The parks collectively contain nearly 159 rides and attractions. The firm's revenue is generated from selling access to rides and attractions, charging fees for special event rentals, and collecting regular rental payments from commercial tenants.

About AIM AIM ImmunoTech Inc.

AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders and viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases, and the drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer, and triple-negative metastatic breast cancer. It is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.

Share on Social Networks: